The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS

Hyerim Ha, Jin Hyoung Kang, Do Yeun Kim, Seung Jin Bae, Hee Yeon Lee

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Purpose: Rapid development of novel therapeutics in renal cell carcinoma (RCC) has led to financial burden for patients and society. Value including clinical benefit, toxicity affecting quality of life and cost-effectiveness are a concern, prompting the need for tools to facilitate value assessment of therapeutics. This study reviews the value assessment tools, and evaluates the value of emerging therapeutics in RCC. Materials and methods: Two medical oncologists used American Society of Clinical Oncology value framework (ASCO VF) v2.0 and European Society for Medical Oncology-magnitude of clinical benefit scale (ESMO-MCBS) v1.1 to phase 3 trials evaluating first-line therapy in patients with metastatic RCC. Follow-up (FU) reports and extended survival data were included. Equivocal aspects and limitations of the tools were discussed. Results: Six trials (COMPARZ, CheckMate 214, JAVELIN renal 101, Keynote 426, CLEAR, and CheckMate 9ER) were assessed. The control arm was standard-of-care sunitinib in all trials. ASCO VF’s net health benefit, calculated as clinical benefit, toxicity and other bonus point was 11 in pazopanib, 41.9 in nivolumab plus ipilimumab, 22.4 in axitinib plus avelumab, 48.7 in axitinib plus pembrolizumab, 35.2 in lenvatinib plus pembrolizumab, and 50.8 in cabozantinib plus nivolumab. A higher score means a greater treatment benefit. ESMO-MCBS gave grade 5 to nivolumab plus ipilimumab, 4 to pazopanib, lenvatinib plus pembrolizumab and cabozantinib plus nivolumab, 3 to axitinib plus avelumab or pembrolizumab. Both tools had unclear aspects to be applied to clinical practice, and should be more clearly defined, such as endpoint for determining survival benefits or how to standardize quality of life and toxicity. Conclusions: ASCO VF and ESMO-MCBS were applied to evaluate the newly emerging drugs in RCC and assessed their value. In-depth discussion by experts in various fields is required for appropriate clinical application in a real-world setting.

Original languageEnglish
Article number900
JournalBMC Health Services Research
Issue number1
StatePublished - Dec 2022

Bibliographical note

Funding Information:
This work was supported by the INHA UNIVERSITY Research Grant.

Publisher Copyright:
© 2022, The Author(s).


  • ASCO value framework
  • Carcinoma, renal cell
  • Immune checkpoint inhibitor
  • Tyrosine kinase inhibitor
  • Values


Dive into the research topics of 'The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS'. Together they form a unique fingerprint.

Cite this